Aptamers

News Aptamers

• First live targeting of tumors with RNA-based technology

  Finding and treating a tumor without disturbing normal tissue presents challenges – sometimes the most effective therapies can be invasive and harsh. Researchers at Duke University Medical Center have devised a way they might deliver the right therapy directly to tumors using special molecules, call more

• New biosensor can detect bacteria instantaneously

  A research group from the Rovira i Virgili University (URV) in Tarragona has developed a biosensor that can immediately detect very low levels of Salmonella typhi , the bacteria that causes typhoid fever. The technique uses carbon nanotubes and synthetic DNA fragments that activate an electric signa more

• NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12

  NOXXON Pharma AG announced that the company was awarded a research grant from Germany's Federal Ministry of Education and Research (BMBF) under the ministry's small and medium enterprise innovation initiative ("KMU-Innovativ"). The grant was presented to NOXXON following the completion of a peer re more

Publications Aptamers

• Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs [ARTICLES]

  Due to structural flexibility, RNase sensitivity, and serum instability, RNA nanoparticles with concrete shapes for in vivo application remain challenging to construct. Here we report the construction of 14 RNA nanoparticles with solid shapes for targeting cancers specifically. These RNA nanopartic more

• The Impact of a Ligand Binding on Strand Migration in the SAM-I Riboswitch

  by Wei Huang, Joohyun Kim, Shantenu Jha, Fareed Aboul-ela Riboswitches sense cellular concentrations of small molecules and use this information to adjust synthesis rates of related metabolites. Riboswitches include an aptamer domain to detect the ligand and an expression platform to control gene more

• Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth [Medical Sciences]

  Aptamers, oligonucleotides able to avidly bind cellular targets, are emerging as promising therapeutic agents, analogous to monoclonal antibodies. We selected from a DNA library an aptamer specifically recognizing human epidermal growth factor receptor 2 (ErbB-2/HER2), a receptor tyrosine kinase, wh more

Market studies Aptamers

• NascaCell Technologies AG (N7C) - Financial and Strategic SWOT Analysis Review

  Nascacell Technologies AG (Nascacell) is a publicly held company specialized in the development of products and drug development candidates based on the proprietary Microbody technology. The company offers a range of new generation biomolecules to the healthcare industry. Its customers are spread ac more

Websites Aptamers